Turn Therapeutics Inc.

Turn Therapeutics issued a press release on September 9, 2026 furnished under Reg FD as Exhibit 99.1. The substantive content of the press release was not captured in the excerpt beyond confirming it was a furnished disclosure. This is a routine investor communications filing.

Turn Therapeutics (TTRX) issued a press release on September 9, 2026 furnished as Exhibit 99.1 under Reg FD. The substantive content of the press release was not captured in the excerpt. This is a routine investor communications disclosure for the emerging growth stage company.

Turn Therapeutics Inc. (TTRX) filed an 8-K under Item 3.02 (Unregistered Sales of Equity Securities) on August 13, 2026. Item 3.02 discloses the sale of equity securities — common stock, preferred stock, warrants, or convertible notes — that were issued in a private placement exempt from SEC registration under Regulation D or another exemption. For a development-stage biotech like Turn Therapeutics, such sales are a primary capital-raising mechanism. Investors should review the filing for the type of securities issued, total proceeds raised, the offering price relative to market price, and any conversion or warrant exercise terms that could affect future dilution.

Turn Therapeutics Inc. (TTRX) filed an Item 7.01 (Regulation FD) 8-K on August 14, 2026, to broadly disseminate material information shared in a non-public setting. For a clinical-stage biotechnology company like Turn Therapeutics — which is developing epigenetic medicines targeting aging-related diseases — Reg FD filings typically accompany conference presentations, investor day materials, or pipeline update decks. The attached exhibit likely covers clinical program status, upcoming milestone catalysts, and financial runway commentary. Investors should review the exhibit for any new data, clinical read-outs, or partnership updates that could serve as near-term stock catalysts for this early-stage company.

Turn Therapeutics Inc. filed an 8-K on July 28, 2026 under Item 7.01 to furnish an updated investor presentation as a Regulation FD disclosure. The company, a Westlake Village, California-based emerging growth biotech listed on the Nasdaq, furnished the presentation as an exhibit. Turn Therapeutics is focused on epigenetic therapies and gene regulation; investor presentations of this type typically update the clinical pipeline status, corporate milestones, and financing runway. The presentation is furnished rather than filed, meaning it is not subject to Section 18 Exchange Act liabilities, and is accessible as an exhibit to this filing.

Turn Therapeutics Inc. issued a press release and an updated investor presentation on July 7, 2026 under Regulation FD. Both documents are furnished as exhibits (not filed) and their specific content is not reproduced in the filing body excerpt. Reg FD update — topic and substance are in the attached exhibits; investors should review the press release and investor presentation for any material clinical or pipeline news.

TTRX (TTRX) disclosed its addition to Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 under 8-K Item 8.01 (other events). Index inclusions are significant because they trigger automatic buying from passive index funds and ETFs that track the benchmark, often resulting in increased share price and trading volume. Index providers typically announce additions in advance of the effective rebalancing date, giving institutions time to adjust their holdings. The event increases TTRX's institutional ownership base and enhances its market visibility and liquidity profile.